Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Lennon
PHARMAPRESS CO SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): PHARMAPRESS CO [tablet] COMPOSITION: Each tablet contains: Enalapril maleate 20,0 mg Hydrochlorothiazide 12,5 mg PHARMACOLOGICAL CLASSIFICATION: A : 7.13 - Other hypotensives. PHARMACOLOGICAL ACTION: PHARMAPRESS CO (enalapril maleate/hydrochlorothiazide) is a combination of an angiotensin-converting enzyme inhibitor (enalapril maleate) and a diuretic (hydrochlorothiazide), resulting in an additive anti-hypertensive effect. Enalapril is hydrolysed to enalaprilat, which is the active metabolite. INDICATIONS: PHARMAPRESS CO is indicated for the treatment of hypertension where fixed combination therapy is more appropriate than monotherapy. CONTRA-INDICATIONS: Hypersensitivity to any ingredient of PHARMAPRESS CO. A history of angioneurotic oedema in patients relating to previous treatment with an angiotensin-converting enzyme inhibitor. Hypersensitivity to other sulphonamide-derived medicines. Pregnant and lactating mothers. Anuria. WARNINGS Should a woman become pregnant while receiving an ACE-inhibitor, the treatment must be stopped promptly and switched to a different medicine. Should a woman contemplate pregnancy, the doctor should institute alternative medication. Symptomatic hypotension may occur after the first dose of PHARMAPRESS CO; this is more likely in patients who have received prior diuretic therapy. Prior to initial therapy with PHARMAPRESS CO, diuretic therapy should be discontinued for 2-3 days. When therapy is administered to patients with ischaemic heart or cerebrovascular disease, particular consideration should be given, because an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident. When enalapril has been given concomitantly with a diuretic, some hypertensive patients with Read the complete document